Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Potential Activity of HE3286 When Administered Orally to Obese Adult Subjects for 28 Days.

Next Previous
X
Search
Trial Profile

A Phase I, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Potential Activity of HE3286 When Administered Orally to Obese Adult Subjects for 28 Days.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Jun 2015

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bezisterim (Primary)
  • Indications Insulin resistance; Obesity; Type 2 diabetes mellitus
  • Focus Adverse reactions; Biomarker; Pharmacokinetics
  • Sponsors Harbor Therapeutics

    • Most Recent Events

    • 12 Nov 2009 Status changed from recruiting to completed according to a Hollis-Eden Pharmaceuticals media release. The final analysis of this trial is currently in progress.
    • 19 Jun 2009 Planned end date changed from 1 Sep 2008 to 1 Sep 2009 as reported by ClinicalTrials.gov.
    • 17 Nov 2008 Planned number of patients changed from 54 to 66, as reported by ClinicalTrials.gov. Trial centres updated.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top